Signalling profile differences: paliperidone versus risperidone. - Wikidata - awgldk - TriplyDB

Signalling profile differences: paliperidone versus risperidone.

Signalling profile differences: paliperidone versus risperidone.

http://www.wikidata.org/entity/Q41906281

about

A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder An update of safety of clinically used atypical antipsychotics.Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials.Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism.Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Discovery of new GPCR ligands to illuminate new biology.Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity

P2860

Q26766541-FA67DBF1-CEF2-4E8A-961D-054D3EB16670 Q36062184-E5E5627E-BA99-455C-84A6-951E6A4FC516 Q37299914-53526920-37B4-4882-A2AD-D4CCAA2D3ACC Q37488898-6587C686-E0A9-4C95-A822-D18340646E34 Q38648544-11319340-98A2-4CDD-83EC-33FEA20F3938 Q38694725-678E0AD8-E22F-45C8-BD0B-E024E7F6B070 Q38779847-52FA718F-80CE-4B45-B647-4885992E63AC Q38811433-88AB11CE-84C4-40D2-A83E-19F24BB8FE8C Q40215868-A30EBF76-001A-4575-AC4F-749DE1C6CFC1 Q41250110-01BAB522-13F6-4B7C-9DDD-9A017308354D Q46344527-FD91EDBD-2293-4E54-A6C8-EC4FC48D0343 Q58798205-97E59BFF-66D7-4F8C-A4BE-1D3188C8A9CB

P2860

Signalling profile differences: paliperidone versus risperidone.

http://www.wikidata.org/entity/Q41906281

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Signalling profile differences: paliperidone versus risperidone.

@en

type

label

Signalling profile differences: paliperidone versus risperidone.

@en

prefLabel

Signalling profile differences: paliperidone versus risperidone.

@en

P1433

Q41906281-2429671D-D631-4134-A140-84FAC228EFC2

P1476

Q41906281-409C3CBF-0DBF-4C86-BCE9-41972AA2E8F8

P2093

Q41906281-051144D4-5EE1-482A-924E-A178659B7A23

Q41906281-12B1B6EC-8C5B-491E-9294-13605DC5748B

Q41906281-84D20F39-956E-4080-83E8-8DA41C7775C5

Q41906281-A082AD75-3BD0-4EE4-8A68-69A0D5DF4DAB

Q41906281-E4CE43D1-CFA7-448B-B383-9810F6D2058D

P2860

Q41906281-02856F29-8976-475E-9AFD-6F0797DF952D

Q41906281-02B3BC39-D85F-41B9-87D2-5DA2F7A74458

Q41906281-02E568AC-477E-4164-9E8C-1BA1778C2E68

Q41906281-0A63DF6E-54C2-4D5C-B314-67C86F262CAF

Q41906281-0BCE5A8F-078B-4AAB-B69D-DE391A0BB779

Q41906281-0C4DEBCA-3580-4A65-8431-BC584C6B57CA

Q41906281-145C08A6-5445-4584-9A18-CA229665A297

Q41906281-1E5FF281-8861-4D51-8FA1-72A14ECB8CFE

Q41906281-291597A5-021C-4A39-8360-7C2660A52614

Q41906281-29C9430E-9340-45D2-AFF5-D46A0B922D09

P304

Q41906281-151C568C-ABD4-442C-9118-33E3F360156A

P31

Q41906281-E55F8FE8-A054-48A5-B5A0-9940D00C99B7

P356

Q41906281-47BF2DE4-C47D-40F0-AAF2-318339234B27

P407

Q41906281-CF330346-3E5F-4471-B8C2-4ACE8D427FB0

P433

Q41906281-A56733D9-8970-4F99-8FF5-073DBBADF7D9

P478

Q41906281-BE8E48F2-F659-4110-B209-1A5FA9D40DE9

P577

Q41906281-4881AF7C-9A1B-40C4-BCBC-1E2D3C5AD314

P698

Q41906281-D5798E97-EDAC-4A3A-80ED-F4BB5F273688

P932

Q41906281-9DEF7F2A-A4A1-44AF-87D0-9CE47E5F5BA8

P356

P1433

British Journal of Pharmacology

P1476

Signalling profile differences: paliperidone versus risperidone.

@en

P2093

K A Berg

http://www.w3.org/2001/XMLSchema#string

L C Sullivan

http://www.w3.org/2001/XMLSchema#string

M Silva

http://www.w3.org/2001/XMLSchema#string

T A Chavera

http://www.w3.org/2001/XMLSchema#string

W P Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors

Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

The physiology, signaling, and pharmacology of dopamine receptors

RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity

Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses

Molecular targets for treating cognitive dysfunction in schizophrenia.

P304

532-545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BPH.12295

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23826915

http://www.w3.org/2001/XMLSchema#string

P932

3791992

http://www.w3.org/2001/XMLSchema#string